Orion OyjSTU:OFK -1.06%87 Return-on-Tangible-Asset is 19.48% as of Mar. 2026, which is 17% below its 10-year median of 23.49. GuruFocus rates STU:OFK with a GF Score™ of 87/100 and a GF Value™ of €71.54 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,009 Drug Manufacturers companies, Orion Oyj ranks better than 98.32% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Orion Oyj's annualizedNet Income for the quarter that ended in Mar. 2026 was €362 Mil. Orion Oyj's average total tangible assets for the quarter that ended in Mar. 2026 was €1,856 Mil. Therefore, Orion Oyj's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 19.48%.
The historical rank and industry rank for Orion Oyj's Return-on-Tangible-Asset or its related term are showing as below:
STU:OFK'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 17 Med: 23.49 Max: 32.05
Current: 32.05
During the past 13 years, Orion Oyj's highest Return-on-Tangible-Asset was 32.05%. The lowest was 17.00%. And the median was 23.49%.
STU:OFK's Return-on-Tangible-Asset is ranked better than 98.32% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs STU:OFK: 32.05
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Orion Oyj Return-on-Tangible-Asset Related Terms
Orion Oyj Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Orion Oyj's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:OFK vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Orion Oyj's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Orion Oyj's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 19.48% mean?
Orion Oyj (STU:OFK) has a Return-on-Tangible-Asset of 19.48% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Orion Oyj and its competitors. This is 17% below median its historical median of 23.49. Over the past decade, Orion Oyj's Return-on-Tangible-Asset has ranged from 17.00 to 32.05. According to the industry distribution chart, Orion Oyj ranks #17 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 1.7%.
Is Orion Oyj's Return-on-Tangible-Asset too high?
Orion Oyj's current Return-on-Tangible-Asset of 19.48% is 17% below median its 10-year median of 23.49. Over the past 10 years, this metric has ranged from a low of 17.00 to a high of 32.05. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. Orion Oyj's value of 19.48% is 516.5% above this industry median. Based on the distribution chart, Orion Oyj ranks #17 out of 1009 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orion Oyj has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #17 out of 1009 companies for Return-on-Tangible-Asset. This places Orion Oyj in the top 2% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.16. Orion Oyj's value of 19.48% is 516.5% above this benchmark. Historically, Orion Oyj's own Return-on-Tangible-Asset has ranged from 17.00 to 32.05 over the past decade. While the company's 10-year median is 23.49 vs. the industry median of 3.16, Orion Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Oyj's current Return-on-Tangible-Asset of 19.48% is 516.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Orion Oyj and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Oyj's current Return-on-Tangible-Asset is 19.48%, which is 17% below median its own 10-year median of 23.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Based on GuruFocus' analysis, Orion Oyj (STU:OFK) is currently considered Fairly Valued. The stock's GF Value™ is €71.54, compared to a current price of €69.70 — trading 2.6% below its estimated fair value. The current Return-on-Tangible-Asset is 19.48%, which is 17% below median its 10-year median of 23.49 and 516.5% above the Drug Manufacturers industry median of 3.16. Orion Oyj's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Orion Oyj (STU:OFK), the current Return-on-Tangible-Asset is 19.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (STU:OFK) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be undervalued.
The current stock price of €69.70 is trading 2.6% below its estimated GF Value™ of €71.54.
GuruFocus considers Orion Oyj to be Fairly Valued.
Key valuation signals for STU:OFK:
Return-on-Tangible-Asset: 19.48% (17% below median its 10-year median of 23.49)
GF Value™: €71.54 vs. price of €69.70 (2.6% below fair value)
Industry Position: 516.5% above the Drug Manufacturers median (#17 of 1009)
No single metric tells the full story. See the STU:OFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
87GF Score
Get the complete analysis for STU:OFK
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OFK has been successfully added to your 
